Literature DB >> 11732752

Comparison of vaginal aminopeptidase enzymatic activities in various animals and in humans.

F Acartürk1, Z I Parlatan, O F Saracoğlu.   

Abstract

The specific enzymatic activity of four different aminopeptidases (aminopeptidase N, leucine aminopeptidase, aminopeptidase A and aminopeptidase B) in vaginal homogenates from rabbit, rat, guinea-pig, sheep and humans was compared. The purpose of the study was to find an appropriate animal model that can be used in degradation studies of protein and peptide drugs. Different substrates were used as the relative specific substrates for the determination of aminopeptidase enzymatic activity: 4-methoxy-2-naphthylamide of L-alanine for aminopeptidase N, 4-methoxy-2-naphthylamide of L-leucine for leucine aminopeptidase, 4-methoxy-2-naphthylamide of L-glutamic acid for aminopeptidase A and 4-methoxy-2-naphthylamide of L-arginine for aminopeptidase B. The vaginal aminopeptidase enzymatic activity of different species was determined spectrofluorometrically. The inhibition of aminopeptidase activity in the presence of bestatin and puromycin inhibitors was also investigated. The results showed the presence of aminopeptidase enzymatic activity in all vaginal homogenates in the order: sheep > guinea-pig > rabbit > or = human > or = rat. Based on the results of the hydrolysis and inhibition of the 4-methoxy-2-naphthylamide substrates, it was difficult to have an exact decision on the aminopeptidase type in the vaginal homogenates from the species studied. It was found that the aminopeptidase activity in rat, rabbit and humans was not statistically different. Therefore, we suggest that rats and rabbits could be used as model animals for vaginal enzymatic activity studies and for determination of the degradation of protein and peptide drugs in the vagina.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732752     DOI: 10.1211/0022357011778034

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

Review 1.  Vaginal drug delivery systems for HIV prevention.

Authors:  Lisa Cencia Rohan; Alexandra B Sassi
Journal:  AAPS J       Date:  2009-02-05       Impact factor: 4.009

Review 2.  Modifications in Vaginal Microbiota and Their Influence on Drug Release: Challenges and Opportunities.

Authors:  Gerardo Leyva-Gómez; María L Del Prado-Audelo; Silvestre Ortega-Peña; Néstor Mendoza-Muñoz; Zaida Urbán-Morlán; Maykel González-Torres; Manuel González-Del Carmen; Gabriela Figueroa-González; Octavio D Reyes-Hernández; Hernán Cortés
Journal:  Pharmaceutics       Date:  2019-05-06       Impact factor: 6.321

3.  Ovarian Follicular Growth through Intermittent Vaginal Gonadotropin Administration in Diminished Ovarian Reserve Women.

Authors:  Chao-Chin Hsu; Isabel Hsu; Li-Hsuan Lee; Rosie Hsu; Yuan-Shuo Hsueh; Chih-Ying Lin; Hui Hua Chang
Journal:  Pharmaceutics       Date:  2022-04-15       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.